Wegovy Pill Approved in the UK: Can You Buy It Yet?
The MHRA approved the Wegovy pill (semaglutide tablets) for weight management in the UK on 11 June 2026. As of 12 June 2026, the Wegovy pill has been approved but is not yet commercially available in the UK.
For most patients, the key question is not whether the pill is approved - it is whether they can actually get it. Approval and availability are separate steps.
Wegovy pill UK status at a glance
| Item | Status |
|---|---|
| MHRA approved | Yes - 11 June 2026 |
| Available to buy privately | Not yet confirmed |
| UK launch date | Not announced |
| UK private price | Not announced |
| Available on the NHS | No - pending NICE review |
| Prescription required | Yes |
Can you buy the Wegovy pill today?
As of 12 June 2026, the Wegovy pill has been MHRA-approved but has not launched commercially in the UK. Check registered UK pharmacy services for confirmed prescribing availability before taking any steps to access it. Do not buy from any site offering it without a prescription.
Pharmacist comment
"The approval of the Wegovy pill is significant because it gives patients who do not want injections another licensed weight management option. Patients should be aware that approval and availability are different steps; pricing, launch dates and prescribing guidance are still to be confirmed. Anyone currently on Wegovy injections should not switch without speaking to their prescriber first."
-Sorin Romaniuc, Pharmacist, Medino
People also ask about the Wegovy pill
Is the Wegovy pill approved in the UK?
Yes. The MHRA approved the Wegovy pill on 11 June 2026, making it the first GLP-1 tablet licensed specifically for weight management in the UK.
Can I buy the Wegovy pill yet?
Not yet. Approval does not mean the medicine is immediately stocked in pharmacies. No confirmed commercial launch date has been announced as of 12 June 2026.
Will the Wegovy pill be available on the NHS?
No, not currently. NHS access requires a separate NICE cost-effectiveness review, which has not yet begun.
How much will the Wegovy pill cost in the UK?
No UK price has been confirmed. Pricing will be announced by Novo Nordisk and pharmacy services at commercial launch.
What MHRA approval actually changes
Approval is not the same as availability. Before the MHRA decision, certain things simply could not legally happen in the UK. After it, those barriers are removed, but new steps still apply before any patient can access the medicine.
| Before MHRA approval | After MHRA approval |
|---|---|
| Cannot legally be marketed for weight loss in the UK | Can be marketed for weight loss in the UK |
| UK pharmacies cannot stock it | Pharmacies can stock it once commercially launched |
| Prescribers cannot prescribe the licensed UK product | Prescribers can prescribe once available |
| No NHS assessment process can begin | NICE can begin a formal cost-effectiveness review |
| No UK list price can be set | Novo Nordisk can announce and agree UK pricing |
Approval is the gate that opens all of these. But it does not complete any of them automatically. Each step takes additional time.
Has the MHRA approved the Wegovy pill?
Yes. The MHRA approved the Wegovy pill on 11 June 2026, confirmed in an official press release on GOV.UK. MHRA Executive Director Julian Beach stated it had "met the MHRA's rigorous standards of safety, quality and effectiveness" and confirmed it is a prescription-only medicine.
The approved indication covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 with at least one weight-related health condition such as type 2 diabetes, high blood pressure or cardiovascular disease. It is licensed for use alongside a reduced-calorie diet and increased physical activity.
The dose escalation schedule is: 1.5 mg → 4 mg → 9 mg → 25 mg once daily, with a minimum of one month at each level. The full Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL) will be published on the MHRA Products website within seven days of approval; prescribers should verify details against those documents once available.
What is the Wegovy pill?
The Wegovy pill is a once-daily oral tablet containing semaglutide, licensed for weight management in adults. Here is what patients need to know quickly:
- Active ingredient: Semaglutide - the same as in the Wegovy injection and Rybelsus
- Dosing: Once daily, at the same time each morning
- Taking instructions: Fasting required - see "How to take the Wegovy pill" below
- Prescription required: Yes - it cannot be bought without a clinical consultation
- Not the same as the Wegovy injection: The injection is once weekly; the pill is once daily
- Not the same as Rybelsus: Rybelsus is licensed for type 2 diabetes at up to 14 mg; the Wegovy pill is licensed for weight management at up to 25 mg
- Manufacturer: Novo Nordisk
It works by mimicking the GLP-1 hormone naturally released after eating, acting on areas of the brain that regulate appetite to promote fullness and reduce hunger.
Why does the Wegovy pill contain 25 mg when the injection is only 2.4 mg?
Because oral semaglutide is absorbed much less efficiently than injected semaglutide, the tablet contains a higher dose to achieve similar drug levels in the body.
The doses cannot be compared directly. They refer to very different amounts reaching the bloodstream.
When semaglutide is injected under the skin, it enters the bloodstream directly and efficiently. When taken as a tablet, it must survive the stomach environment - an acidic, enzyme-rich space designed to break down substances - before being absorbed. This is extremely difficult for peptide molecules like semaglutide.
The Wegovy pill uses a special absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which briefly changes the stomach environment to allow semaglutide to pass through the stomach lining before digestive enzymes break it down. Even with this technology, only a small proportion of the oral dose typically reaches the bloodstream - which is why the dose is so much higher than the injection.
A 25 mg tablet and a 2.4 mg injection may achieve broadly comparable drug levels in the bloodstream despite the large difference in stated dose.
This also explains the strict taking instructions. If the tablet is taken with food, with a large quantity of water, or immediately before eating, absorption drops further - potentially making the medicine significantly less effective.
Is the Wegovy pill available in the UK now?
Not yet. Approval and availability are separate things.
Novo Nordisk has indicated that it expects private prescriptions to become available within weeks of the approval, but no confirmed commercial launch date has been announced. Patients should not assume availability based on the approval date alone. Medino will update this page when confirmed information is available.
When will the Wegovy pill launch in the UK?
No confirmed UK launch date has been announced.
After approval, a commercial launch requires Novo Nordisk to finalise UK list pricing, distribute stock to pharmacy wholesalers, onboard registered dispensing pharmacies and provide clinical guidance to prescribers. Each of these takes time that is not governed by the approval date.
For NHS access, a NICE appraisal in England is required before the medicine can be recommended for NHS prescribing. No NICE review timeline has been announced.
Monitor regulated UK pharmacy services for confirmed stock and prescribing updates.
What we expect to happen next
Based on the pattern of previous GLP-1 medicine launches in the UK, here are the milestones to watch:
| Milestone | What to look for |
|---|---|
| SmPC and PIL publication | Full prescribing information, contraindications, missed dose guidance - due within 7 days of 11 June 2026 |
| UK list price announcement | Novo Nordisk confirms private pricing; pharmacies begin publishing costs |
| First pharmacy stock allocation | Registered UK services announce confirmed prescribing availability |
| NICE review announcement | NICE publishes scope or appraisal timeline for England |
| NHS prescribing pathway | NICE issues guidance; NHS commissioners implement access criteria |
UK pharmacy availability tracker
As of 12 June 2026, no selected UK online pharmacy has announced a confirmed launch date or private price for the Wegovy pill.
| Pharmacy | Launch date announced? | Pricing announced? |
|---|---|---|
| Medino | Not yet | Not yet |
| Pharmica | Not yet | Not yet |
| Simple Online Pharmacy | Not yet | Not yet |
| Oxford Online Pharmacy | Not yet | Not yet |
| Numan | Not yet | Not yet |
| Voy | Not yet | Not yet |
Last checked: 12 June 2026. This table will be updated as pharmacies confirm availability and pricing.
Can you buy the Wegovy pill online?
Not yet. When it launches, it will be a prescription-only medicine, legally available only through a registered UK prescriber following a proper clinical consultation.
When confirmed availability is announced, the expected access routes are:
- GPhC-registered online pharmacies with integrated prescribing services
- Regulated private prescribing clinics
- NHS pathways, if and when NICE recommends funding
Do not purchase from any site that does not require a proper clinical consultation. Do not import from the United States or any other country - medicines sourced outside the licensed UK supply chain may be counterfeit, improperly stored or incorrectly labelled.
You can verify whether a pharmacy is GPhC-registered at pharmacyregulation.org. Report concerns about unlicensed medicine supply to the MHRA at yellowcard.mhra.gov.uk.
How much will the Wegovy pill cost in the UK?
No UK private price has been confirmed. Pricing will be announced by Novo Nordisk and UK pharmacy services at launch.
UK pricing will depend on the dose prescribed, the pharmacy or service used, and whether consultation and prescription fees are bundled. It may also vary as competition develops in this market.
Will the Wegovy pill be available on the NHS?
Not currently. The MHRA has confirmed in its official press release: "Whilst this tablet is approved for use in the UK, it is not available currently via the NHS. As with all new treatments, decisions on NHS use will follow established processes, including an evaluation by the National Institute for Health and Care Excellence (NICE)."
NICE carries out a separate cost-effectiveness assessment before recommending NHS funding in England. This process typically takes months to years after initial approval. Until NICE issues guidance and NHS commissioners implement it, the Wegovy pill will not be routinely available on the NHS.
Scotland has an equivalent process through the Scottish Medicines Consortium (SMC). Wales and Northern Ireland have separate commissioning decisions.
Wegovy pill vs Wegovy injection
| Feature | Wegovy pill | Wegovy injection |
|---|---|---|
| Form | Oral tablet | Subcutaneous injection pen |
| How taken | Swallowed whole with water | Injected under the skin |
| Dosing frequency | Once daily | Once weekly |
| Starting dose | 1.5 mg | 0.25 mg |
| Maximum approved dose | 25 mg | 2.4 mg (standard); 7.2 mg (newly approved) |
| Fasting required | Yes - 8 hours before; 30 min after | No |
| Storage | Room temperature | Refrigerated before first use |
| Needles | No | Yes |
| NHS availability | Not yet | Limited; specialist services only |
| Private availability | Not yet launched | Currently available |
| Prescription required | Yes | Yes |
The MHRA approval documents indicate that patients currently treated with the 2.4 mg weekly injection may be able to transition to the 25 mg daily tablet, but any switch should only be made under prescriber supervision. Do not change formulation without speaking to your prescriber first.
Neither form is objectively superior. Weight loss results from the OASIS 4 trial (pill) are broadly comparable to those from the STEP 1 trial (injection). The most appropriate choice depends on individual clinical circumstances, lifestyle, tolerability and prescriber assessment.
Wegovy pill vs Mounjaro
Mounjaro (tirzepatide) is the other major GLP-1 weight management medicine available privately in the UK, and it is the comparison patients most commonly want to see alongside the Wegovy pill.
There are currently no published head-to-head clinical trials comparing the Wegovy pill against Mounjaro specifically. The comparison below draws on separate trial programmes and should be interpreted cautiously.
| Feature | Wegovy pill | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 and GIP receptor agonist |
| Form | Once-daily oral tablet | Once-weekly injection |
| Prescription required | Yes | Yes |
| UK weight management licence | Yes (MHRA approved June 2026) | Yes (MHRA approved) |
| NHS availability | No - pending NICE review | Limited |
| Private availability | Not yet launched | Currently available |
| Fasting required for dosing | Yes | No |
| Needles | No | Yes |
Clinical trials suggest both medicines can produce substantial weight loss, but there are currently no published head-to-head trials comparing the Wegovy pill against Mounjaro directly. The practical distinction most patients will feel is format: the pill requires daily dosing with fasting; Mounjaro is a once-weekly injection which does not require fasting or timing around meals.
For a detailed clinical comparison, see Medino's Mounjaro vs Wegovy guide. The best treatment for any individual depends on their medical history, clinical goals and prescriber assessment.
Is the Wegovy pill the same as Rybelsus?
No - and this matters clinically.
Rybelsus is an oral semaglutide tablet licensed for type 2 diabetes management, with a maximum dose of 14 mg daily. The Wegovy pill is a separately licensed oral semaglutide tablet for weight management in adults with obesity or overweight, with a maximum dose of 25 mg daily.
Both are made by Novo Nordisk and work through the same mechanism, but they carry separate product licences, different approved indications and different dose ranges. A person prescribed Rybelsus for diabetes should not use it for weight management - and vice versa - without explicit prescriber guidance.
Who may be eligible for the Wegovy pill?
Based on the MHRA approval, the Wegovy pill may be prescribed to adults with:
- A BMI of 30 kg/m² or above (obesity), or
- A BMI of 27 to 29.9 kg/m² (overweight) with at least one weight-related health condition
Eligibility requires a full clinical assessment. Meeting BMI criteria alone does not guarantee suitability. Prescribers will review individual medical history, current medications, contraindications and clinical goals before prescribing.
The medicine is intended for use alongside a reduced-calorie diet and increased physical activity, not as a standalone intervention.
Who should not take the Wegovy pill?
Full contraindications will be set out in the SmPC and PIL, which will be published within seven days of the 11 June approval. Based on the known profile of semaglutide, contraindications and precautions may include:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide or any formulation excipient
- Severe gastrointestinal disease
- Pregnancy
This is not exhaustive. Always consult a healthcare professional and read the PIL before starting treatment.
Wegovy pill side effects
The MHRA confirms the most common side effects are gastrointestinal: nausea, diarrhoea, constipation and vomiting. These are consistent with the wider GLP-1 class and typically are most pronounced when starting treatment or increasing the dose, improving over time with continued use.
In the OASIS 4 trial, approximately 6.9% of participants taking oral semaglutide discontinued due to adverse events - consistent with discontinuation rates in injectable semaglutide trials.
Serious side effects requiring prompt medical attention may include severe abdominal pain (which could indicate pancreatitis), signs of allergic reaction or a markedly rapid heartbeat.
Report suspected side effects to the MHRA Yellow Card scheme: yellowcard.mhra.gov.uk.
How effective is the Wegovy pill?
The approval is based primarily on the OASIS 4 phase 3 clinical trial: 307 adults with obesity or overweight (with at least one weight-related condition), without diabetes, over 64 weeks alongside lifestyle modifications.
- Intention-to-treat analysis (all participants regardless of adherence): ~13.6% weight loss with semaglutide 25 mg versus ~2.4% with placebo
- Per-protocol analysis (participants who remained fully adherent): ~16.6% versus ~2.7%
Individual results vary considerably. These are mean figures from a controlled trial population. Weight loss depends on adherence, diet, physical activity and individual response. The Wegovy pill does not guarantee any specific outcome.
How to take the Wegovy pill
Per the MHRA, the Wegovy pill must be taken correctly to achieve adequate absorption:
- Take on an empty stomach after fasting for at least eight hours
- Swallow whole with a small sip of water only - not a full glass, not coffee, not juice
- Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medicines
Eating or drinking too soon after the tablet substantially reduces its absorption and may significantly reduce its effectiveness. This daily fasting requirement is more demanding than the Wegovy injection, which has no food-timing restrictions.
What happens next: the full timeline
| Stage | What it means | Status as of 12 June 2026 |
|---|---|---|
| Clinical trial evidence | OASIS 4 and supporting data submitted | Completed |
| MHRA review | Assessed safety, quality and effectiveness | Approved - 11 June 2026 |
| SmPC and PIL publication | Official prescribing and patient documents | Within 7 days of approval |
| Commercial launch | Novo Nordisk makes product available to UK pharmacies | Not yet confirmed |
| Private prescribing | GPhC-registered pharmacies begin dispensing | Not yet confirmed |
| NICE review (England) | Cost-effectiveness assessment for NHS | Not yet started |
| SMC review (Scotland) | Scottish equivalent of NICE review | Not yet started |
| NHS access | Eligible patients may access through NHS pathways | Not available |
What should patients do now?
If you are interested in the Wegovy pill:
- Monitor regulated UK pharmacy services for confirmed launch information.
- Do not import from overseas, and do not buy from any site that does not require a proper clinical consultation.
- When it launches, complete a thorough consultation with a registered UK prescriber to confirm eligibility.
If you are already taking Wegovy injections:
- Do not switch without speaking to your prescriber. Any transition from the injection to the pill should be managed under clinical supervision.
- The injection remains available privately while the pill becomes commercially established.
If you are considering weight management medicine for the first time:
- Speak to your GP or a registered prescriber to discuss your options and suitability.
- A proper clinical consultation is required - the Wegovy pill, like all GLP-1 medicines, is prescription-only.
If the Wegovy pill becomes available through UK online pharmacies, patients should complete a regulated consultation to check whether it is suitable for them.
Key takeaway
The MHRA's approval of the Wegovy pill on 11 June 2026 is meaningful. It is the first GLP-1 tablet licensed specifically for weight management in the UK, and it gives patients who cannot or do not want to inject a potential regulated alternative.
But approved does not mean available. The pill has not yet launched commercially, has no confirmed UK price and is not available on the NHS. A NICE review is required before NHS funding can be considered.
The right approach for any patient is to wait for confirmed regulated UK access - and to avoid any unregulated route to obtain the medicine.
Frequently asked questions
1. Has the MHRA approved the Wegovy pill? Yes. The MHRA granted marketing authorisation on 11 June 2026, as confirmed in an official press release on GOV.UK. The UK is the first country in Europe to approve it.
2. Is the Wegovy pill available in the UK? Not yet, as of 12 June 2026. Approval has been granted, but commercial launch has not been confirmed. Novo Nordisk has indicated private prescriptions may become available within weeks. Check registered UK pharmacy services for updates.
3. When will the Wegovy pill be available in the UK? No confirmed UK launch date has been announced. Monitor registered pharmacy services for updates. NHS availability will require a NICE review and is not expected in the near term.
4. Can I buy the Wegovy pill online in the UK? Not yet. When it launches, it will only be legally available through GPhC-registered pharmacies following a prescription from a registered UK prescriber. Do not buy from any site offering it without a proper assessment.
5. How much will the Wegovy pill cost? No UK price has been confirmed as of 12 June 2026. Pricing will be announced by Novo Nordisk and pharmacy services at launch. Check back for updates once the commercial launch is confirmed.
6. Will the Wegovy pill be available on the NHS? Not currently. The MHRA has confirmed a NICE evaluation must take place before NHS use can be considered. No timeline for that review has been announced.
7. Is the Wegovy pill the same as Wegovy injections? No. Both contain semaglutide, but they are different products: different formulations, different doses, different dosing frequencies and different administration methods.
8. Is the Wegovy pill better than the injection? Neither is objectively better. Trial data shows broadly comparable weight loss between the pill and the standard 2.4 mg injection. The pill requires no injections; the injection requires dosing only once weekly. The best choice depends on individual clinical circumstances.
9. Is the Wegovy pill the same as Rybelsus? No. Both are oral semaglutide tablets but carry separate licences. Rybelsus is approved for type 2 diabetes at up to 14 mg. The Wegovy pill is approved for weight management at up to 25 mg.
10. Is the Wegovy pill oral semaglutide? Yes. It contains semaglutide in an oral tablet formulation using the SNAC absorption enhancer to allow stomach absorption.
11. Do you need a prescription for the Wegovy pill? Yes. The MHRA has confirmed it is a prescription-only medicine. It cannot be legally obtained without a valid prescription following a clinical consultation.
12. Who can take the Wegovy pill? Adults with a BMI of 30 or above, or adults with a BMI of 27 to 29.9 with at least one weight-related health condition. Eligibility requires clinical assessment by a registered prescriber.
13. What are the side effects of the Wegovy pill? The most common side effects are nausea, diarrhoea, constipation and vomiting. These are typical of the GLP-1 class and usually most pronounced at treatment initiation and dose escalation. Report any concerning side effects to a healthcare professional and to the MHRA Yellow Card scheme.
14. Can I switch from Wegovy injections to the Wegovy pill? The MHRA approval documents indicate that a transition from the 2.4 mg weekly injection to the 25 mg daily tablet may be possible in appropriate patients, but any switch must be made under prescriber supervision. Do not change formulation without speaking to your prescriber first.
15. Can I import the Wegovy pill from another country? No. Importing prescription medicines from overseas is not a safe or regulated route to access medicine in the UK. Wait for confirmed UK availability through registered services.
16. Is the Wegovy pill safe? The MHRA has assessed it against rigorous standards for safety, quality and effectiveness and has granted approval. Like any prescription medicine, it carries potential side effects and is not suitable for everyone. A clinical consultation is required to assess individual suitability.
17. How does the Wegovy pill work? It contains semaglutide, which mimics the GLP-1 hormone naturally released after eating. Per the MHRA, it acts on areas of the brain that regulate appetite, helping people feel fuller for longer, reducing hunger and decreasing food cravings. It must be taken on an empty stomach because oral absorption of semaglutide requires very specific conditions.
18. How often do you take the Wegovy pill? Once daily, on an empty stomach after an eight-hour fast, with no food or drink for at least 30 minutes afterwards. This contrasts with the injection, which is taken once weekly with no food restrictions.
19. Why is the Wegovy pill 25 mg when the injection is only 2.4 mg? The doses cannot be compared like-for-like. Oral semaglutide must survive the stomach before being absorbed, so only a small proportion of the tablet dose reaches the bloodstream. The higher milligram number compensates for this - it does not mean the pill is stronger. See the full explanation in the "Why does the Wegovy pill contain 25 mg" section above.
20. Why do you have to take the Wegovy pill on an empty stomach? Because absorption of the oral semaglutide tablet depends on a specific stomach environment. Food, drink and other medicines change that environment and significantly reduce how much semaglutide can pass through the stomach lining before being broken down. Taking the tablet with food can substantially reduce its effectiveness, which is why the eight-hour fast and 30-minute post-dose window are required - not optional.
21. Can you drink coffee after taking the Wegovy pill? No, not within the first 30 minutes. The MHRA's guidance is that no food or drink - including coffee - should be consumed for at least 30 minutes after taking the tablet. Only a small sip of plain water is permitted when swallowing the pill itself. Drinking coffee or any other liquid too soon can reduce absorption and reduce the medicine's effectiveness.
22. What happens if you miss a dose of the Wegovy pill? The full prescribing guidance for the Wegovy pill will be published in the SmPC and PIL within seven days of the 11 June 2026 approval. In general, for daily oral medicines, if a dose is missed it is typically advised to skip it and resume the next day rather than doubling up - but patients should follow the specific guidance in the PIL and speak to their prescriber or pharmacist if unsure.
23. Is the Wegovy pill stronger than the Wegovy injection? No. The higher milligram dose in the pill does not mean greater potency - it compensates for the fact that oral semaglutide is much less efficiently absorbed than injected semaglutide. Weight loss results from the OASIS 4 trial (pill) are broadly comparable to results from the STEP 1 trial (standard 2.4 mg injection). They are different formulations designed to achieve similar drug levels in the body.
24. Will the Wegovy pill be easier to get than Wegovy injections? It is too early to say. Injectable Wegovy has faced significant supply constraints in the UK since its launch. Whether the pill faces similar issues will depend on manufacturing capacity, demand and Novo Nordisk's supply strategy. The pill will also require a prescription and clinical assessment, so it will not be available over the counter. Monitor registered UK services for confirmed availability.
25. What should I do if I see the Wegovy pill for sale online? Do not buy it. Any site selling the Wegovy pill without a proper prescription, or before a confirmed UK commercial launch through a registered service, is operating outside the law. Verify pharmacy registration at pharmacyregulation.org and report concerns to the MHRA at yellowcard.mhra.gov.uk.
Reviewed by: Sorin Romaniuc, GPhC number: 2221337 Last updated: 12 June 2026 This article is for general information only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping or switching any prescription medicine.
